GLP-1 drugs such as Ozempic, Wegovy and Zepbound are growing in popularity to treat patients in need of significant weightloss, but they're expensive. Medicaid programs in 13 states cover ...
As of this summer, about 12% of U.S. adults said they had been on a GLP-1 receptor agonist — the class of drugs that includes Ozempic and Wegovy — for either weightloss or treatment of ...